Andy I. Chen
-
- Lymphoma Diagnosis and Treatment 22
- Oncology top 5%
- CAR-T cell therapy research 9
- Viral-associated cancers and disorders 6
- HER2/EGFR in Cancer Research 5
- Genetics top 5%
- Chronic Lymphocytic Leukemia Research 9
- Immunology top 5%
- Immune Cell Function and Interaction 5
- Neurology top 5%
-
- Cutaneous lymphoproliferative disorders research 6
-
- Monoclonal and Polyclonal Antibodies Research 4
- Co-authors
- Arlene H. SharpeVeronika BachanováCraig H. MoskowitzPatrick J. StiffMuneer H. AbidiJerzy HołowieckiJohn SweetenhamAnna Sureda
- Journals
- Blood (11 papers)Journal of Clinical Oncology (6 papers)Biology of Blood and Marrow Transplantation (4 papers)
- Partner nations
- United StatesItalyPoland
In The Last Decade
Andy I. Chen
36 papers receiving 1.5k citations
Hit Papers
Peers
Comparison fields: 5 of 71
- Pathology and Forensic Medicine 829
- Oncology 797
- Genetics 278
- Immunology 552
- Neurology 284
Countries citing papers authored by Andy I. Chen
This map shows the geographic impact of Andy I. Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andy I. Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andy I. Chen more than expected).
Fields of papers citing papers by Andy I. Chen
This network shows the impact of papers produced by Andy I. Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andy I. Chen. The network helps show where Andy I. Chen may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Andy I. Chen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 6 | |
| 2 | 2024 | 13 | |
| 3 | 2023 | 3 | |
| 4 | 2022 | 14 | |
| 5 | 2021 | 0 | |
| 6 | 2019 | 93 | |
| 7 | 2018 | 67 | |
| 8 | 2018 | 2 | |
| 9 | 2016 | 12 | |
| 10 | Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trialbreakdown → | 2015 | 477 |
| 11 | 2015 | 21 | |
| 12 | 2014 | 11 | |
| 13 | 2013 | 16 | |
| 14 | 2012 | 11 | |
| 15 | 2011 | 4 | |
| 16 | 2008 | 8 | |
| 17 | 2008 | 80 | |
| 18 | 2007 | 3 | |
| 19 | 2002 | 93 | |
| 20 | 1999 | 254 |
About Andy I. Chen
Andy I. Chen is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology, having authored 38 papers that have together received 1.5k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (22 papers), Chronic Lymphocytic Leukemia Research (9 papers), CAR-T cell therapy research (9 papers), Cutaneous lymphoproliferative disorders research (6 papers), Viral-associated cancers and disorders (6 papers), Immune Cell Function and Interaction (5 papers), HER2/EGFR in Cancer Research (5 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). The work is most often cited by research in Pathology and Forensic Medicine (829 citations), Oncology (797 citations) and Genetics (278 citations). Andy I. Chen has collaborated with scholars based in United States, Italy and Poland. Frequent co-authors include Arlene H. Sharpe, Veronika Bachanová, Craig H. Moskowitz, Patrick J. Stiff, Muneer H. Abidi, Jerzy Hołowiecki, John Sweetenham, Anna Sureda, Jan Walewski and Tamás Masszi. Their work appears in journals such as Blood, Journal of Clinical Oncology, Biology of Blood and Marrow Transplantation, Blood Advances and Immunity.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.